A Case of Multiple Tuberculosis Associated with Infliximab Therapy in Crohn's Disease / 대한내과학회지
Korean Journal of Medicine
; : 337-341, 2012.
Article
em Ko
| WPRIM
| ID: wpr-165635
Biblioteca responsável:
WPRO
ABSTRACT
Infliximab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, has been approved for the treatment of a variety of inflammatory illnesses, including Crohn's disease. However, infliximab can increase the risk of reactivation of latent tuberculosis (Tbc) infection by affecting host immune responses. Therefore, a screening test should be performed before the initiation of infliximab therapy, and patients with evidence of latent infection should be treated with prophylactic anti-Tbc therapy. Here, we report a case of multifocal disseminated tuberculosis after treatment with infliximab in a patient diagnosed with Crohn's disease who had no past history of Tbc and showed a negative screening test.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Tuberculose
/
Doença de Crohn
/
Programas de Rastreamento
/
Fator de Necrose Tumoral alfa
/
Tuberculose Latente
/
Infliximab
/
Anticorpos Monoclonais
Tipo de estudo:
Prognostic_studies
/
Screening_studies
Limite:
Humans
Idioma:
Ko
Revista:
Korean Journal of Medicine
Ano de publicação:
2012
Tipo de documento:
Article